NCT04740034 - A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

AMG 340

AMG 340 is a bispecific antibody targeting prostate-specific membrane antigen (PSMA) on tumor cells and CD3 on T-cells

Trial Locations (7)

Icahn School of Medicine at Mount Sinai, New York

Thomas Jefferson University - Sidney Kimmel Cancer Center, Philadelphia

Florida Cancer Specialists, Sarasota

Tennessee Oncology, Nashville

Tulane Cancer Center, New Orleans

Sarah Cannon Research Institute at HealthONE, Denver

UCSF, San Francisco